While cancer vaccines have been in clinical trials for more than a decade, to date we have witnessed limited success with only one product (Provenge) approved by the FDA in 2010 to treat prostate cancer in men that have not received chemotherapy. However, the efforts of companies and researchers were not for nothing as lots of data have been collected that would help one day to create a cancer vaccine that would overcome past difficulties. In this article, we will focus on Heat Biologics (NASDAQ:HTBX), a vaccine technology company that is developing various cellular therapeutic vaccines for a range of cancers and infectious diseases. While the company is at an earlier stage of development versus others in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|